• Corpus ID: 29276166

Allele Frequency of CYP2C19 Gene Polymorphisms in a Healthy Iranian Population

@article{Zand2005AlleleFO,
  title={Allele Frequency of CYP2C19 Gene Polymorphisms in a Healthy Iranian Population},
  author={Negin Zand and Tajik Nader and Mehdi Hourmand and Salek Moghadam Ali Reza and Iraj Milanian},
  journal={Iranian Journal of Pharmacology and Therapeutics},
  year={2005},
  volume={4},
  pages={124-128},
  url={https://api.semanticscholar.org/CorpusID:29276166}
}
Genotypes of CYP2C19 in Iranian population are determined to compare allele frequencies with previous findings in other ethnic groups and there was no difference between frequency of CYp2C 19 allelic variants in this study and other evaluated Caucasians.
bioline.org.br
20 Citations
Highly Influential Citations
2
Background Citations
5
Methods Citations
6
Results Citations
2

Tables from this paper

20 Citations

Investigation of CYP2C19 allele and genotype frequencies in Iranian population using experimental and computational approaches.

CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip.

The distribution of CYP2C19*2 in the Gaza Strip population is lower than that in Caucasians, Africans and the Asian populations and the role of other CYPs' polymorphisms in the patient group is investigated.

Frequency distribution of high risk alleles of CYP2C19, CYP2E1, CYP3A4 genes in Haryana population.

CYPs Genotyping, Essential Hypertension and Frequencies of Mutant Alleles in an Uzbek Population

It is found that the *2/*2 polymorphism of the CYP2C9-2 gene was associated with EH in Uzbek hypertensive patients, and monogenic Western and hybrid Eastern population of Uzbekistan are often carriers of damaging *1/*3-*3/*3 genotype of CYP3A5 gene.

SCREENING FOR CYP2C19*2, *3 AND *4 GENE VARIANTS IN A ROMANIAN POPULATION STUDY GROUP

The distribution of the CYP2C19 alleles in thr population studied matches data from reports on other Caucasian populations, and can represent the basis of establishing the best CYP 2C19 genotyping protocol in individuals who are prescribed CYP1C19 substrates in Romania.

Cytochrome P450 2C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients: in vitro and in silico studies

The role of CYP2C19 gene polymorphisms in susceptibility to CML population is provided and the molecular basis of malignancies caused is explored which may aid in the development of precise medicine or adjusting the drug dosages so as to reduce the chemotherapeutic side effects.

Genetic Polymorphism of CYP2C19 in Pakistani Population

The high allele frequency of PM (CYP2C19*2 and *17) in Pakistani population led to the recommendation of a pre-treatment test to monitor drug response and dosage (personalized medicine) to avoid post-treatment adverse drug reactions.

Prevalence of CYP2C19 polymorphisms in the Lebanese population

Data show no significant difference in the frequency of CYP2C19 allelic variants when compared to Caucasian populations and demonstrate that the application of the recent FDA recommendations would also be beneficial in Lebanon, allowing physicians to identify patients at high risk for atherothrombotic events, and eventually advising them to consider other antiplatelet medications or alternative dosing strategies in poor metabolizers.

Prevalence of CYP2C19 Genetic Polymorphism among Normal People and Patients with Hepatic Diseases

The distribution of CYP2C19 genotype frequencies in Iranian healthy people and patients with various hepatic diseases was not significantly different, which may allow the physicians to predict a tailoring dose regimens based on the individual’s metabolic capacity, decrease the risk of harmful side effects of the drugs, and optimize the treatment.

Effect of Cyp2c19*2 Polymorphism on the Pharmacokinetics of Gliclazide in Healthy Myanmar Volunteers

It is suggested that CYP2C19*2 polymorphism affect the metabolism of gliclazide but not its absorption, as shown in the results of this study.

15 References

Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

Three new potentially defective alleles of CYP2C19 occur in African-Americans, or individuals of African descent, and are predicted to alter risk of these populations to clinically important drugs.

A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.

This study provides unequivocal evidence for autosomal recessive inheritance of the PM trait and examines the specificity and sensitivity of the CYP2C19 genotyping test.

Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.

This study examined whether the genotype predicted the phenotype in Japanese, Filipino and Saudi Arabian populations, and compared the frequencies of the defective CYP2C19 alleles in these populations with those found in European-Americans, Chinese-Taiwanese, and African-Americans from North Carolina.

Cytochrome P450 Enzyme System: Genetic Polymorphisms and Impact on Clinical Pharmacology

The cytochrome P450 (CYP) enzyme system is involved in the metabolism and elimination of numerous widely used drugs. The capacity of this system varies from one person to another, leading to variable…

Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.

The existence and frequency of various low-activity alleles of drug metabolizing enzymes as well as populational drug metabolic capacities are compared among several different races or ethnicities.

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.

The phenotype determined by omeprazole correlated with that of mephenytoin, and was in good agreement with the genotype.

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

Interethnic differences in debrisoquin and mephenytoin hydroxylation have been compared between normal white (n = 183) and Japanese (n = 100) subjects with the 8‐hour urinary metaboUc ratio of…